{"id":"NCT00666263","sponsor":"Baxalta now part of Shire","briefTitle":"Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy","officialTitle":"A Randomized, Double-Blind, Placebo Controlled, Cross-over Study of the Effectiveness of Immune Globulin Intravenous (Human), 10% (IGIV, 10%) for the Treatment of Multifocal Motor Neuropathy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-08-22","primaryCompletion":"2011-08-11","completion":"2011-08-11","firstPosted":"2008-04-24","resultsPosted":"2013-03-13","lastUpdate":"2021-05-19"},"enrollment":50,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Multifocal Motor Neuropathy"],"interventions":[{"type":"BIOLOGICAL","name":"Immune Globulin Intravenous (human), 10%","otherNames":["IGIV, 10%","GAMMAGARD LIQUID","KIOVIG"]},{"type":"BIOLOGICAL","name":"0.25% human albumin solution (Placebo)","otherNames":["BUMINATE 25%, Albumin (Human) Solution","Human Albumin 200 g/L Baxter"]}],"arms":[{"label":"IGIV, 10% Then Placebo","type":"EXPERIMENTAL"},{"label":"Placebo Then IGIV, 10%","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to evaluate the efficacy (effect on grip strength and disability) and safety/tolerability of IGIV, 10% in subjects with Multifocal Motor Neuropathy.","primaryOutcome":{"measure":"Grip Strength in the More Affected Hand","timeFrame":"Week 0, then at Last infusion cycle for each study part (Day 8 of last treatment cycle for 2-week interval or Day 15 of last treatment cycle for 3 or 4 -week interval), then at the end of study visit","effectByArm":[{"arm":"Before Stabilization 1","deltaMin":18.14,"sd":null},{"arm":"End of Stabilization 1","deltaMin":21.68,"sd":null},{"arm":"End of Cross-Over 1","deltaMin":19.54,"sd":null},{"arm":"End of Stabilization 2","deltaMin":19.39,"sd":null},{"arm":"End of Cross-Over 2","deltaMin":11.28,"sd":null},{"arm":"End of Stabilization 3","deltaMin":17.77,"sd":null},{"arm":"End of the Study","deltaMin":17.37,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":15},"locations":{"siteCount":17,"countries":["United States","Canada","Denmark"]},"refs":{"pmids":["11971045","10467380"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":44},"commonTop":["NEUROLOGICAL DECOMPENSATION","HEADACHE","MUSCLE SPASMS","UPPER RESPIRATORY TRACT INFECTION","INFLUENZA LIKE ILLNESS"]}}